195 related articles for article (PubMed ID: 22549158)
21. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
22. MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway.
Gu ZW; He YF; Wang WJ; Tian Q; Di W
J Zhejiang Univ Sci B; 2019 Mar.; 20(3):219-237. PubMed ID: 30829010
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
[TBL] [Abstract][Full Text] [Related]
24. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
26. Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.
Zhang L; Liu P; Li H; Xue F
Mol Med Rep; 2013 May; 7(5):1705-9. PubMed ID: 23504001
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of long non-coding RNA antisense non-coding RNA in the INK4 locus suppresses OVCAR-3 cells proliferation and induction of apoptosis by Wnt/β-catenin.
Sun L; Cui Y; Jiang K; Li J
J Pharm Pharmacol; 2021 Aug; 73(9):1212-1217. PubMed ID: 33772549
[TBL] [Abstract][Full Text] [Related]
28. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.
Jordaan G; Liao W; Sharma S
BMC Cancer; 2013 Feb; 13():88. PubMed ID: 23432814
[TBL] [Abstract][Full Text] [Related]
29. Hyper-activation of WNT/β-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
Shao N; Zou J; Li J; Chen F; Dai J; Qu X; Sun X; Ma D; Ji C
Leuk Lymphoma; 2012 Sep; 53(9):1769-78. PubMed ID: 22303878
[TBL] [Abstract][Full Text] [Related]
30. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
[TBL] [Abstract][Full Text] [Related]
32. Identifying microRNA/mRNA dysregulations in ovarian cancer.
Miles GD; Seiler M; Rodriguez L; Rajagopal G; Bhanot G
BMC Res Notes; 2012 Mar; 5():164. PubMed ID: 22452920
[TBL] [Abstract][Full Text] [Related]
33. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
Mithraprabhu S; Khong T; Spencer A
Cell Death Dis; 2014 Mar; 5(3):e1134. PubMed ID: 24651437
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a
McDonald JI; Diab N; Arthofer E; Hadley M; Kanholm T; Rentia U; Gomez S; Yu A; Grundy EE; Cox O; Topper MJ; Xing X; Strissel PL; Strick R; Wang T; Baylin SB; Chiappinelli KB
Cancer Res; 2021 Oct; 81(20):5176-5189. PubMed ID: 34433584
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
36. MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
Zhai Y; Iura A; Yeasmin S; Wiese AB; Wu R; Feng Y; Fearon ER; Cho KR
Oncogene; 2011 Oct; 30(40):4152-62. PubMed ID: 21499300
[TBL] [Abstract][Full Text] [Related]
37. miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression.
Liu L; Ning Y; Yi J; Yuan J; Fang W; Lin Z; Zeng Z
Biomed Pharmacother; 2020 May; 125():109865. PubMed ID: 32058212
[TBL] [Abstract][Full Text] [Related]
38. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
39. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
40. MiR-27a promotes EMT in ovarian cancer through active Wnt/𝜷-catenin signalling by targeting FOXO1.
Zhang LY; Chen Y; Jia J; Zhu X; He Y; Wu LM
Cancer Biomark; 2019; 24(1):31-42. PubMed ID: 30614794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
